Alkermes Plc ALKS:NASDAQ

Last Price$15.15NASDAQ Previous Close - Last Trade as of 3:59PM ET 4/06/20

Today's Change+1.03(7.29%)
Bid (Size)$15.20 (1)
Ask (Size)$15.69 (6)
Day Low / High$14.26 - 15.17
Volume2.2 M

View Biotechnology IndustryPeer Comparison as of 04/06/2020


Alkermes Plc ( NASDAQ )

Price: $15.15
Change: +1.03 (7.29%)
Volume: 2.2 M
3:59PM ET 4/06/2020

Prothena Corporation PLC ( NASDAQ )

Price: $11.87
Change: +1.52 (14.69%)
Volume: 265.0 K
3:59PM ET 4/06/2020

Nabriva Therapeutics PLC ( NASDAQ )

Price: $0.52
Change: -0.004 (0.76%)
Volume: 2.9 M
3:56PM ET 4/06/2020

Iterum Therapeutics PLC ( NASDAQ )

Price: $2.60
Change: -0.05 (1.89%)
Volume: 22.1 K
3:38PM ET 4/06/2020

Read more news Recent News

--Analyst Actions: Morgan Stanley Drops Price Target for Alkermes to $16 From $20, Maintains Equal Weight Rating
2:54PM ET 4/02/2020 MT Newswires

Price: 13.60, Change: -0.30, Percent Change: -2.16 ...

Analysts' Scale Down Alkermes' 2020, 2021 Earnings Estimates
11:40PM ET 3/23/2020 MT Newswires

The 2020 and 2021 full year forecasted earnings estimates for Alkermes Plc's (NASDAQ:ALKS, Recent Price: 13.38) have been lowered. The consensus for 2020,...

Alkermes' New-Drug Application for Acute Schizophrenia Treatment Under FDA Review
11:14AM ET 3/04/2020 MT Newswires

Alkermes (ALKS) said Wednesday that its new-drug application for ALKS 3831, for the treatment of patients with acute schizophrenia, is currently under...

Insider Trends: Alkermes Insider Converts Option/Derivative Security Sells Portion to Pay Tax, Buy Trend Intact
5:09PM ET 3/03/2020 MT Newswires

Richard F Pops, and Director and CEO, Alkermes Plc, exercised options/derivative securities for 17,500 shares of Alkermes (ALKS) and sold 7,770 shares in...

View all Commentary and Analysis

Alkermes: Lack Of Near-Term Catalysts
2:54PM ET 3/13/2020 Seeking Alpha

Stocks To Watch: Time For Coronavirus Offense Or Defense?
8:26AM ET 2/29/2020 Seeking Alpha

IPO Update: Passage Bio Finalizes $126 Million IPO Plan
3:57PM ET 2/18/2020 Seeking Alpha

Alkermes plc (ALKS) CEO Richard Pops on Q4 2019 Results - Earnings Call Transcript
2:12PM ET 2/13/2020 Seeking Alpha

Company Profile

Business DescriptionAlkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland. View company web site for more details
AddressConnaught House
Dublin, Dublin D04 C5Y6
Number of Employees2,300
Recent SEC Filing04/03/20204
Chairman & Chief Executive OfficerRichard F. Pops
Senior Vice President-OperationsDeclan O'Connor
Chief Financial Officer & Senior Vice PresidentJim Frates
Chief Medical Officer & EVP-Research & DevelopmentCraig C. Hopkinson

Company Highlights

Price Open$14.58
Previous Close$15.15
52 Week Range$11.98 - 37.75
Market Capitalization$2.4 B
Shares Outstanding157.8 M
SectorHealth Technology
Next Earnings Announcement04/23/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.71
Beta vs. S&P 500N/A
Revenue$1.1 B
Net Profit Margin-16.79%
Return on Equity-18.09%

Analyst Ratings as of 02/14/2020

Consensus RecommendationConsensus Icon
Powered by Factset